imurek i.v.
aspen pharma trading limited (8134622) - azathioprin-natrium (1:x) ((mit angaben zur zusammensetzung)) - pulver zur herstellung einer injektions- bzw. infusionslösung - teil 1 - pulver zur herstellung einer injektions- bzw. infusionslösung; azathioprin-natrium (1:x) ((mit angaben zur zusammensetzung)) (06400) 54,1 milligramm
imurek 50 mg filmtabletten
aspen pharma trading limited (8134622) - azathioprin - filmtablette - teil 1 - filmtablette; azathioprin (04347) 50 milligramm
bupivan 5 mg/ml injektionslösung
eugia pharma (malta) limited (1010127) - bupivacainhydrochlorid 1 h<2>o - injektionslösung - teil 1 - injektionslösung; bupivacainhydrochlorid 1 h<2>o (22131) 5 milligramm
mecain 10 mg/ml injektionslösung durchstechflasche
eugia pharma (malta) limited (1010127) - mepivacainhydrochlorid - injektionslösung - teil 1 - injektionslösung; mepivacainhydrochlorid (05638) 10 milligramm
xaluprine (previously mercaptopurine nova laboratories)
nova laboratories ireland limited - 6-mercaptopurin-monohydrat - leukämie, lymphoid - antineoplastische mittel - xaluprine ist indiziert zur behandlung von akuter lymphoblastischer leukämie (all) bei erwachsenen, jugendlichen und kindern.
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karzinom, plattenepithelkarzinom - antineoplastische mittel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
fenikren 20 mg/5 mg/12,5 mg filmtabletten
sigillata limited (8187417) - olmesartanmedoxomil; amlodipinbesilat; hydrochlorothiazid - filmtablette - 20 mg/5 mg/12,5 mg - teil 1 - filmtablette; olmesartanmedoxomil (27955) 20 milligramm; amlodipinbesilat (24866) 6,93 milligramm; hydrochlorothiazid (00512) 12,5 milligramm
fenikren 40 mg/5 mg/12,5 mg filmtabletten
sigillata limited (8187417) - olmesartanmedoxomil; amlodipinbesilat; hydrochlorothiazid - filmtablette - 40 mg/5 mg/12,5 mg - teil 1 - filmtablette; olmesartanmedoxomil (27955) 40 milligramm; amlodipinbesilat (24866) 6,93 milligramm; hydrochlorothiazid (00512) 12,5 milligramm
scandicain 1 %
aspen pharma trading limited (8134622) - mepivacainhydrochlorid - injektionslösung - mepivacainhydrochlorid (05638) 10 milligramm
scandicain 2 %
aspen pharma trading limited (8134622) - mepivacainhydrochlorid - injektionslösung - mepivacainhydrochlorid (05638) 20 milligramm